African Americans experience longer delays between diagnosis and treatment of prostate cancer

May 28, 2013

Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study suggests that efforts are needed to reduce racial disparities in prostate cancer care in order to provide earlier treatment for African Americans.

To see if there is a difference in the time from cancer diagnosis to initiation of treatment for compared with with prostate cancer, Ronald Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and his colleagues analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare registry, which links cancer diagnosis data to a master file of Medicare records. Their analysis included 2,506 African American and 21,454 Caucasian patients diagnosed with early (non-metastatic) prostate cancer from 2004 to 2007 and treated within 12 months of diagnosis.

On average, the time from prostate cancer diagnosis to initiation of treatment was seven days longer overall for African American patients compared with Caucasian patients. In the group of patients with aggressive, or high risk, prostate cancer, the average number of days from diagnosis to surgery or was 96 days for Caucasian patients, and 105 days for African American patients.

"This study contributes to a growing body of studies demonstrating the disparities in care and outcomes among African American and Caucasian prostate cancer patients in this country. African American patients are less likely than to undergo prostate cancer screening, more likely to be diagnosed with advanced cancer, have longer delays from diagnosis to treatment, as demonstrated by this study, and are less likely to receive aggressive treatment," said Dr. Chen. "All of these factors together can contribute to an increased rate of dying from prostate cancer in African American compared to Caucasian prostate cancer patients."

Dr. Chen added that additional studies are needed to assess what personal or institutional factors may delay treatment for African American patients and to determine if any interventions can help eliminate this disparity.

Explore further: African Americans experience longer delay between prostate cancer diagnosis and treatment

More information: "Racial differences in time from prostate cancer diagnosis to treatment initiation, a population-based study."; William A. Stokes, Laura H. Hendrix, Trevor J. Royce, Ian M. Allen, Paul A. Godley, Andrew Z. Wang, and Ronald C. Chen. CANCER; Published Online: May 28, 2013 (DOI: 10.1002/cncr.27975).

Related Stories

African Americans experience longer delay between prostate cancer diagnosis and treatment

April 1, 2013
African American men on average wait a week longer than their Caucasian counterparts between the initial diagnosis of prostate cancer and treatment, according to University of North Carolina researchers.

Exercise linked with reduced prostate cancer risk in Caucasians but not African Americans

February 11, 2013
A new study suggests that exercise may reduce Caucasian men's risk of developing prostate cancer. And among Caucasian men who do have prostate cancer, exercise may reduce their risk of having more serious forms of the disease. ...

Early-onset baldness in African-American men may be linked to prostate cancer

March 26, 2013
Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, according to data published in Cancer Epidemiology, ...

Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy

May 20, 2013
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...

Particular DNA changes linked with prostate cancer development and lethality

April 22, 2013
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.